Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

This study is testing a combination of two drugs — talazoparib (a PARP inhibitor that disrupts cancer cell DNA repair) and enzalutamide (a hormone-blocking drug) — given before surgery in men with high-risk prostate cancer, to shrink the tumour and potentially improve surgical outcomes. **You may be eligible if...** - You have prostate adenocarcinoma that a urologist believes could be surgically removed after a response to treatment - You are planning to have a radical prostatectomy (surgical removal of the prostate) at the end of the study period - Your overall health is adequate (ECOG 2 or better) - You meet specific staging criteria (e.g., confirmed lymph node involvement, or other high-risk features) **You may NOT be eligible if...** - Your cancer has spread to distant organs beyond the lymph nodes - You have certain heart conditions or liver problems - You have previously received hormone therapy or chemotherapy for prostate cancer Talk to your doctor to see if this trial is right for you.